With over 30 years of experience, Mark Urtz specializes in interventional procedures, study design, and medical device testing, contributing to advancements in preclinical cardiovascular and neuroscience research.

Endpoint Preclinical is proud to welcome Mark Urtz, BS, to our Expert Network. Mark’s extensive career includes leadership roles in academia and industry, where he performed thousands of interventional procedures and developed expertise in study design and medical device testing. As a consultant, Mark has worked with leading medical device companies worldwide, helping to evaluate novel technologies and navigate complex regulatory requirements. His focus on technical precision and collaborative study execution makes him an invaluable resource for Endpoint clients. View Mark’s Profile

Interventional Expertise and Techniques: Mark has performed over 15,000 interventional procedures across a wide range of applications. His technical capabilities include:

• Coronary and Peripheral Interventions: Advanced vascular procedures to evaluate therapeutic efficacy and device performance.
• Electrophysiology and Renal Denervation: Precision techniques for targeted interventions and neural modulation.
• Valve Placement and Neuromodulation: Expertise in percutaneous delivery systems and intracardiac device placement.
• Advanced Imaging Integration: Proficiency in fluoroscopy, IVUS, OCT, and intracardiac echo to guide interventional procedures with accuracy and efficiency.

Study Design and Protocol Development: Mark has decades of experience designing and managing preclinical studies, ensuring compliance with GLP standards and regulatory requirements. His contributions include:

• Developing customized protocols tailored to study objectives.
• Coordinating multi-phase projects from proof-of-concept to FDA submission studies.
• Collaborating with sponsors to align technical execution with regulatory expectations.

Data Collection and Analysis: Mark’s expertise in hemodynamic assessment and ECG monitoring supports robust data acquisition for preclinical studies. His capabilities include:

• Arrhythmia Analysis: Identifying and interpreting abnormalities such as atrial fibrillation, PVCs, and heart rate variability.
• Regulatory Reporting: Preparing detailed reports for IND filings and pre-market approval submissions, aligning data with 21CFR Part 58 GLP standards.

Mark has trained countless professionals in interventional techniques, focusing on:

• Best practices for percutaneous access and device deployment.
• Integrating imaging modalities into preclinical procedures.
• Mentoring teams to independently execute complex interventional studies.

Mark’s expertise supports diverse preclinical research applications, including:

• Cardiovascular Research: Developing and testing therapies for coronary artery disease, heart failure, and vascular conditions.
• Neuroscience Studies: Advancing neuromodulation and neural intervention techniques.
• Medical Device Testing: Evaluating novel technologies for safety and efficacy in preclinical models.

Join us in welcoming Mark Urtz to Endpoint Preclinical. His extensive experience in interventional procedures and study design strengthens our ability to deliver innovative solutions for medical device and biotechnology clients. Contact us to learn how Mark can support your preclinical research needs.